参考文献

参考文献

［1］Bray F，Ferlay J，Soerjomataram I，et al.Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2018，68（6）：394-424.

［2］Zeng H，Chen W，Zheng R，et al.Changing cancer survival in China during 2003-15：a pooled analysis of 17 population-based cancer registries［J］.Lancet Glob Health，2018，6（5）：e555-e567.

［3］Groot V P，Rezaee N，Wu W，et al.Patterns，timing，and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma［J］.Ann Surg，2018，267（5）：936-945.

［4］He C，Huang X，Zhang Y，et al.A quantitative clinicopathological signature for predicting recurrence risk of pancreatic ductal adenocarcinoma after radical resection［J］. Front Oncol，2019，9：1197.

［5］Witkowski ER，Smith JK，Tseng JF.Outcomes following resection of pancreatic cancer［J］.J Surg Oncol，2013，107（1）：97-103.

［6］Yang XP，Liu SL，Xu JF，et al.Pancreatic stellate cells increase pancreatic cancer cells invasion through the hepatocyte growth factor／cmet／survivin regulated by P53／P21［J］.Exp Cell Res，2017，357（1）：79-87.

［7］Zheng B，Qu J，Ohuchida K，et al.LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of Pancreatic Cancer［J］.Theranostics，2020，10（22）：10274-10289.

［8］Carstens JL，Yang S，Correa de Sampaio P，et al.Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer［J］.Cell Reports，2021，35（2）：108990.

［9］Kajioka H，Kagawa S，Ito A，et al.Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis［J］.Cancer Letters，2021，497：1-13.

［10］Huo Y，Zhou Y，Zheng J，et al.GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil［J］.Frontiers in Immunology，2022，13：983116.

［11］Bin Sheng Wong，Daniel J Shea，Panagiotis Mistriotis，et al.A direct podocalyxin-dynamin-2 interaction regulates cytoskeletal dynamics to promote migration and metastasis in pancreatic cancer Cells［J］.Cancer Res，2019，79（11）：2878-2891.

［12］Wei D，Le X，Zheng L，et al.Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis［J］.Oncogene，2003，22（3）：319-329.

［13］Xiong HQ，Abbruzzese JL，Lin E，et al.NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells［J］.Int J Cancer，2004，108（2）：181-188.

［14］Costa-Silva B，Aiello NM，Ocean AJ，et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver［J］.Nat Cell Biol，2015，17（6）：816-826.

［15］Nielsen SR，Quaranta V，Linford A，et al. Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis［J］.Nat Cell Biol，2016，18（5）：549-560.

［16］Grunwald B，Harant V，Schaten S，et al.Pancreatic premalignant lesions secrete tissue inhibitor of metalloproteinases-1，which activates hepatic stellate cells via CD63 signaling to create a premetastatic niche in the liver［J］.Gastroenterology，2016，151（5）：1011-1024 e7.

［17］Gleisner AL，Assumpcao L，Cameron JL，et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified？［J］.Cancer，2007，110（11）：2484-2492.

［18］Seelig SK，Burkert B，Chromik AM，et al.Pancreatic resections for advanced M1-pancreatic carcinoma：the value of synchronous metastasectomy［J］.HPB Surg，2010，2010：579672.

［19］Tachezy M，Gebauer F，Janot M，et al.Synchronous resections of hepatic oligometastatic pancreatic cancer：Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis［J］.Surgery，2016，160（1）：136-144.

［20］Yu X，Gu J，Fu D，et al.Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma？A systematic review and meta-analysis［J］.Int J Surg，2017，48：149-154.

［21］Hackert T，Niesen W，Hinz U，et al. Radical surgery of oligometastatic pancreatic cancer［J］.Eur J Surg Oncol，2017，43（2）：358-363.(https://www.daowen.com)

［22］Conroy T，Desseigne F，Ychou M，et al.Folfirinox versus gemcitabine for metastatic pancreatic cancer［J］.N Engl J Med，2011，364（19）：1817-1825.

［23］Von Hoff DD，Ervin T，Arena FP，et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine［J］.N Engl J Med，2013，369（18）：1691-1703.

［24］Moore MJ，Goldstein D，Hamm J，et al.Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer：a phaseⅢtrial of the National Cancer Institute of Canada Clinical Trials Group［J］.J Clin Oncol，2007，25（15）：1960-1966.

［25］Hurwitz HI，Uppal N，Wagner SA，et al.Randomized，double-blind，phaseⅡstudy of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed［J］.J Clin Oncol，2015，33（34）：4039-4047.

［26］Hua YQ，Wang P，Zhu XY，et al.Radiofrequency ablation for hepatic oligometastatic pancreatic cancer：An analysis of safety and efficacy［J］.Pancreatology，2017，17（6）：967-973.

［27］Vogl TJ，Mohamed SA，Albrecht MH，et al. Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases：MR-based tumor response evaluation，apparent diffusion coefficient（ADC）patterns，and survival rates［J］.Pancreatology，2018，18（1）：94-99.

［28］Royal RE，Levy C，Turner K，et al.Phase 2 trial of single agent Ipilimumab（anti-CTLA-4）for locally advanced or metastatic pancreatic adenocarcinoma［J］.J Immunother，2010，33（8）：828-833.

［29］Le DT，Lutz E，Uram JN，et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer［J］.J Immunother，2013，36（7）：382-389.

［30］Brahmer JR，Tykodi SS，Chow LQ，et al.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer［J］.N Engl J Med，2012，366（26）：2455-2465.

［31］Feig C，Jones JO，Kraman M，et al.Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer［J］.Proc Natl Acad Sci USA，2013，110（50）：20212-20217.

［32］Bockorny B，Semenisty V，Macarulla T，et al.BL-8040，a CXCR4 antagonist，in combination with pembrolizumab and chemotherapy for pancreatic cancer：the COMBAT trial［J］.Nat Med，2020，26（6）：878-885.

［33］Bockorny B，Macarulla T，Semenisty V，et al. Motixafortide and pembrolizumab combined to nanoliposomal irinotecan，fluorouracil，and folinic acid in metastatic pancreatic cancer：the COMBAT／KEYNOTE-202 Trial［J］. Clinical cancer research：an official journal of the American Association for Cancer Research，2021，27（18）：5020-5027.

［34］Luchini C，Brosens LAA，Wood LD，et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability：histology，molecular pathology and clinical implications［J］.Gut，2021，70（1）：148-156.

［35］Marabelle A，Le DT，Ascierto PA，et al.Efficacy of pembrolizumab in patients With noncolorectal high microsatellite instability／mismatch repair-deficient cancer：results from the phaseⅡKEYNOTE-158 study［J］.J Clin Oncol，2020，38（1）：1-10.

［36］Lawlor RT，Mattiolo P，Mafficini A，et al.Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer：systematic review and still-open questions［J］.Cancers（Basel），2021，13（13）：133119.

［37］Andre T，Shiu KK，Kim TW，et al.Pembrolizumab in microsatelliteinstability-high advanced colorectal cancer［J］.N Engl J Med，2020，383（23）：2207-2218.

［38］Palacio S，McMurry HS，Ali R，et al.DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer［J］.J Gastrointest Oncol，2019，10（6）：1133-1139.

［39］Perkhofer L，Gout J，Roger E，et al.DNA damage repair as a target in pancreatic cancer：state-of-the-art and future perspectives［J］.Gut，2021，70（3）：606-617.

［40］Yu J，Green MD，Li S，et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination［J］.Nat Med，2021，27（1）：152-164.

［41］Wang C，Sandhu J，Ouyang C，et al. Clinical response to immunotherapy targeting programmed cell death receptor 1／programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases［J］. JAMA Netw Open，2021，4（8）：e2118416 doi：10.1001／jamanetworkopen.2021.18416.

［42］Parikh AR，Szabolcs A，Allen JN，et al.Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phaseⅡtrial［J］.Nat Cancer，2021，2（11）：1124-1135.